ArticleOncogene2026
Thr3/Ser90 phosphorylation-stabilized S100A8 regulates cholesterol metabolism in glioblastoma stem cells.
Article in Oncogene, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma (GBM) exhibits profound therapy resistance and inevitable recurrence, driven predominantly by glioblastoma stem cells (GSCs). S100A8 is positively associated with glioblastoma malignancy, but its expression and molecular mechanism in GSCs are poorly understood. Here, we demonstrated that S100A8 was highly expressed in GSCs and closely associated with shorter overall survival in GBM patients. The results showed that S100A8 maintained GSCs stemness by promoting cholesterol synthesis. Mechanistically, S100A8 bound to plasma membrane-localized RAGE, triggering ROS generation. Elevated ROS oxidized intracellular S100A8 at the Cys42 residue, thereby enhancing its affinity for mTORC1, subsequently inducing SREBP2-driven cholesterol synthesis. Furthermore, ROCK1-mediated phosphorylation of S100A8 at Thr3/Ser90, which stabilized S100A8 by impairing its binding to Fbxo10 and inhibiting the subsequent ubiquitination-mediated degradation. Our study reveals the S100A8-ROS-mTORC1 axis as a cholesterol metabolic vulnerability in GSCs, providing new insights into cholesterol metabolism and highlighting novel metabolism therapeutic strategies in GBM.
Indexed as
Identifiers
42009969What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.